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1. Introduction  
Due to an aging population and improved non-invasive cardiac imaging (mainly the wide 
use of transthoracic echocardiography), the number of patients with asymptomatic aortic 
stenosis (AS) is continuously increasing. Aortic stenosis is a progressive active disease 
which can be treated effectively by aortic valve implantation. Therefore, optimal timing of 
surgery is crucial demanding precise risk stratification to identify high-risk but still 
asymptomatic patients. Such patients should undergo close clinical follow-up examination 
or even elective aortic valve replacement. 
Whereas severe symptomatic aortic stenosis is a class I indication for valve replacement, the 
decision to operate on asymptomatic patients remains controversial. Accepted indications 
for aortic valve replacement for asymptomatic patients with severe aortic stenosis are (a) the 
need of cardiac surgery for any other reason such as coronary bypass grafting or surgery of 
the aorta ascendens and (b) if left ventricular systolic dysfunction defined by an ejection 
fraction below 50% occurs. 
The risk of sudden death in asymptomatic severe aortic stenosis without preceding 
symptoms is a matter of concern, although it is regarded as low (around 1% per year) and 
below the perioperative mortality of aortic valve replacement. Otherwise, there is a risk of 
irreversible myocardial damage due to left ventricular hypertrophy and myocardial fibrosis 
if surgery is performed too late.  
The strategy to wait for occurrence of symptoms before indicating aortic valve implantation 
is further challenged by an increased mortality in patients awaiting surgery after onset of 
symptoms, by late symptom reporting by many patients and a higher operative risk for 
more symptomatic patients. 
On the other hand, the immediate operative risk, the long-term morbidity and mortality 
related to the prosthetic aortic valve, and the potential need for re-operation have to be 
taken into account. 
Several risk factors for worse clinical outcome in patients with asymptomatic aortic stenosis 
have been established in the last years. Hemodynamic parameters such as a peak aortic jet 
velocity > 5m/s or a mean gradient > 60 mmHg are used to define very severe aortic 
stenosis, and an increase in peak aortic jet velocity > 0.3 m/s/year define a fast 
hemodynamic progression rate. Whether such high- risk patients should undergo elective 
aortic valve implantation even in the asymptomatic state is still a matter of debate and 
handled differently between European and American Guidelines. Furthermore, interest has 
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shifted to exercise tolerance, degree of valve calcification, the influence of gender or 
systemic parameters such as natriuretic peptides. Among these new non-hemodynamic 
parameters, exercise-induced symptoms are the best validated criterion so far. 
Some patients with aortic stenosis have a reduced stroke volume despite preserved left 
ventricular ejection fraction (referred to as paradoxical low flow aortic stenosis). These 
patients suffer from more pronounced left ventricular concentric remodelling, smaller left 
ventricular cavity, increased global left ventricular load, and reduced midwall shortening. 
They often present with a low transvalvular gradient even though they have a severe 
stenosis on the basis of valve area, and this situation may lead to an underestimation of 
stenosis severity and an underutilization of valve replacement. 
It remains a clinical challenge to balance risk between watchful waiting and early aortic 
valve implantation in patients with asymptomatic aortic stenosis. The physician managing 
these patients has to “look at the valve, listen to the patient” (C. Otto). The decision of aortic 
valve replacement should be taken by cardiologists who “look globally, think globally” (P. 
Pibarot, JG. Dumesnil).  
 
 
  Severe AS (<1cm² or <0.6cm²/m² BSA)   
       
   Symptoms    
 No    Yes  
       
 LVEF<50%      
       
 No   Yes   
       
Markedly calcified valve and 
increase in peak jet 
velocity>0.3m/sec within 1 year 
    
       
 No Yes     
       
Patients physically active     
       
No  Yes     
       
 Exercise test    
 Normal  Abnormal Surgery  
       
Re-evaluate in 6 to 12 months or 
when symptoms occur 
    
       
Fig. 1. Management of patients with severe aortic stenosis (AS). BSA denotes body surface 
area; EF denotes ejection fraction; LV denotes left ventricle (Vahanian  Otto, 2010).  
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2. Assessment of aortic stenosis 
2.1 History 
Aortic stenosis proves the outstanding diagnostic power of a well-taken clinical history. 
Classical symptoms of aortic stenosis are angina pectoris, heart failure, severe cardiac 
arrhythmia such as ventricular tachycardia and syncope. However, these symptoms are 
often preceded by a decreased exercise tolerance or dyspnoe on exertion. It is the skill and 
clinical experience of the physician to discover and interpret these changes correctly in 
patients who may have a low physical activity also for other reasons (e.g. frailty, pulmonary 
disease, obesity, de-conditioning).  
Patients with congenital valvular stenosis may give a history of a murmur since childhood 
or infancy. Those with rheumatic stenosis may have a history of rheumatic fever. The 
influence of sex on the outcome of asymptomatic aortic stenosis is a matter of debate as well. 
Some studies found that female gender is independently predictive of the midterm 
development of symptoms (Monin et al., 2009), but guidelines recommendations so far do 
not differ between genders. 
2.2 Physical findings 
As usual, anamnesis is followed by physical examination. Typical for aortic stenosis is a 
systolic ejection murmur, with a maximum in the 2nd ICR right parasternal with radiation in 
the carotids. In patients with a loud systolic murmur, an echocardiography is indicated. 
Arterial hypertension is present in many patients and imposes additional load on the left 
ventricle by increased vascular resistance. This results in lower transvalvular gradients and 
possible underestimation of stenosis severity, whereas clinical symptoms might occur earlier.  
 
 
Fig. 2. Systolic murmurs in mild and severe aortic stenosis. 
2.3 Echocardiography 
Transthoracic echocardiography supplies the most important information for risk 
stratification of adults with aortic stenosis yielding information about valve anatomy and 
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hemodynamics, the left ventricular response to chronic pressure overload, aortic dilatation 
and associated valve disease. Only in certain circumstances, a transoesophageal or a 3D- 
echocardiography is needed, e.g. for improved analysis of valve anatomy (bicuspid valve, 
planimetry of valve area) or preoperative measurements needed in transcatheter aortic 
valve implantation (TAVI).  
On 2D echocardiography, a stenotic aortic valve is thickened and calcified, with restricted 
opening of the cusps. Three basic parameters are routinely used to assess the hemodynamic 
severity of aortic stenosis: jet velocity, mean transaortic pressure gradient and valve area. 
The aortic jet velocity is measured with continuous wave Doppler from several transducer 
windows, to obtain the signal most parallel with the direction of stenotic jet flow yielding 
the highest velocity signal (Figure 2). For this, color-flow imaging may be helpful to guide 
Doppler beam alignment. Sometimes it is necessary that the patient has to move to a right-
supine position using a right parasternal window and a smaller nonimaging continuous-
wave Doppler transducer (so-called pencil-probe) which is easier to manipulate between the 
ribs. In very small or very tall adults, valve area should be indexed for body size, e.g. to 
avoid that a small person with only a moderate obstruction get the misdiagnosis of a severe 
aortic stenosis.  
 
 
Fig. 3. Using an apical five-chamber view, transvalvular continuous Doppler shows a severe 
to very severe aortic stenosis, with mean/peak systolic gradients of 69 and 98 mmHg, 
respectively, and a peak systolic velocity of 4.9 m/s.  
There are some caveats in the assessment of aortic stenosis by transthoracic 
echocardiography. The measurement of the left ventricular outflow tract diameter has to be 
thoroughly performed from a systolic freeze-frame in the parsternal long-axis view, defined 
by the distance from where the anterior (right aortic) cusp meets the ventricular septum to 
the point where the posterior (noncoronary) cusp meets the anterior mitral leaflet. This may 
be difficult because of heavy calcifications. Furthermore, in patients with atrial fibrillation or 
flutter, velocities should be averaged from 5 to 10 cardiac cycles.   
Whereas systolic left ventricular dysfunction occurs very late in the disease process (mainly 
in symptomatic patients with very severe aortic stenosis who do not undergo valve 
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replacement for whatever reason), left ventricular diastolic dysfunction is frequently found 
in an early phase of aortic stenosis. Left ventricular hypertrophy can be found in most cases 
of severe aortic stenosis.   
 
 
Fig. 4. Left ventricular hypertrophy and restricted aortic cusp movement. 
Four echo parameters permit the classification of aortic stenosis severity. Unfortunately, the 
European Society of Cardiology (ESC) and the American College of Cardiology/ American 
Heart Association (ACC/AHA) differrently interpret mean gradients, as shown in Table 1 
(values in brackets are advised from ACC/AHA). A shortcoming of this classification is that 
one patient may fall in two different categories, e.g. if he has an aortic jet velocity from 3.1 
and an AVA from 1.6 cm2. Notably, guidelines are based on physiological valve area, as 
measured by continuity equation, which differs from anatomical valve area. 
Additional echo parameters who are not yet used in clinical routine are stroke-work loss 
and left ventricular strain analysis. Stroke-work loss is the ratio of mean gradient and left 
ventricular pressure, and a stroke-work loss > 26% results in a major clinical event rate > 
30% within the following three months (Bermejo et al., 2003). 
Patients with systolic dysfunction and small valve area present with low transvalvular 
gradients. It is important to differentiate those with a low gradient due to low stroke volume 
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 Aortic sclerosis Mild AS Moderate AS Severe AS 
Very 
severe AS 
Aortic jet velocity 
(m/s) 
< 2.6 2.6 – 3.0 3.0 – 4.0 > 4.0  > 5.0 
Mean gradient 
(mmHg) 
- < 30 (25) 30 - 50 (25-40) > 50 (40) > 60 
AVA (cm²) - > 1.5 1.0 - 1.5 < 1.0 < 0.6 
Indexed AVA 
(cm²/m²) 
- > 0.9 0.6 - 0.9 < 0.6 - 
Table 1. Categories of aortic stenosis severity, according to ESC (Vahanian et al., 2007) and 
ACC/AHA (Bonow et al., 2008) guidelines. 
 
Severe asymptomatic AS ESC ACC/AHA 
EF < 50% IC 
Undergoing CABG, aortic surgery or mitral valve 
surgery 
IC 
Exercise test 
- symptoms 
- fall in BP to below baseline 
complex ventricular arrhythmias 
 
IC 
IIaC 
IIbC 
 
IIbC 
IIbC 
/ 
Predictors of rapid progression (moderate to severe valve 
calcification, rate of vmax  increase ≥ 0.3 m/s/year IIaC / 
Predictors of rapid progression (age, valve calcification, 
CAD) or if surgery might be delayed at symptom onset 
/ IIbC 
Severe left ventricular hypertrophy (> 15mm) without 
arterial hypertension 
IIbC / 
Extremly severe AS (AVA < 0.6 m2, vmax > 5 m / s, ∆Pmean 
> 60 mmHg) and operative risk < 1% 
/ IIbC 
 
Moderate asymptomatic AS ESC ACC/AHA 
Hemodynamically unstable 
AVR (IB);  BAV (IIbC) as 
bridge to surgery 
 
Indeterminate severity of AS   
Low-gradient AS with left ventricular dysfunction and 
contractile reserve 
IIaC / 
Low-gradient AS with left ventricular dysfunction but no 
contractile reserve 
IIbC / 
Table 2. Guidelines for aortic valve replacement in asymptomatic patients (Vahanian et al., 
2007; Bonow et al., 2008). AVR is recommended in class I indications. AVR is reasonable in 
class IIa and may be considered in class IIb indications. Note that most indications are based 
only on a level of evidence C. EF denotes ejection fraction; CABG denotes coronary artery 
bypass grafting; BP denotes blood pressure; CAD denotes coronary artery disease; BAV 
denotes balloon aortic valvuloplasty. 
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(low-gradient, low-flow AS) from those with a cardiomyopathy and concomitant only 
moderate AS. Dobutamin challenge for low-gradient aortic stenosis and left ventricular 
dysfunction may result in three pattern of responsiveness: fixed aortic stenosis, relative 
aortic stenosis and absence of contractile reserve. A fixed aortic stenosis is characterized by 
an increase in peak velocity > 4 m/s and a mean systolic gradient > 40 mmHg with no 
change in aortic valve area. These patients may still benefit from valve replacement despite 
increased perioperative rsik. In contrast, relative aortic stenosis is characterized by a 
significant increase in calculated aortic valve area (> 0.3 cm2) without a significant increase 
in peak velocity or systolic gradients, whereas no variable changed significantly in patients 
without contractile reserve (lack of increase > 20% of stroke volume).       
2.4 Electrocardiogram 
Resting ECG in severe aortic stenosis usually shows signs of left ventricular hypertrophy, 
often accompanied by repolarisation abnormalities (ST-T-wave changes). Left ventricular 
hypertrophy is an independent predictor for the development of symptoms in 
asymptomatic severe aortic stenosis. However, the sensitivity for detecting left ventricular 
hypertrophy by the electrocardiogram is only 40% (Dal-Bianco et al., 2008). Conduction 
abnormalities are common ranging from first-degree atrio-ventricular block or bundle 
branch block. Atrial fibrillation is not a typical sign of aortic stenosis and may indicate 
concomitant mitral valve disease. 
2.5 Biomarkers 
Natriuretic peptides are secreted from the heart as response to pressure overload. Whereas 
atrial natriuretic peptide (ANP) is produced in the atria, B-type natriuretic peptide (BNP) is 
mainly derived from ventricular myocardium. Obviously, increased intraventricular 
pressure due to significant aortic stenosis is accompanied by elevated plasma levels of BNP 
and its derivatives such as N-terminal pro BNP. Such an elevation of natriuretic peptides 
predict adverse clinical outcome, such as occurrence of symptoms in still asymptomatic 
patients or higher operative mortality or worse post-operative outcome (Bergler-Klein et al., 
2004; Pedrazzini et al., 2008). Systemic inflammation, expressed by elevated plasma CRP 
levels, influence the clinical outcome in advanced stages of aortic stenosis whereas no 
correlation to the progression from aortic sclerosis to aortic stenosis could be found in the 
Cardiovascular Health Study (Galante et al., 2001; Novaro et al., 2007). 
2.6 Exercise test 
An exercise test may be considered for patients with severe AS and equivocal symptoms or 
for asymptomatic, physically active patients with severe AS and slow progression. A stress 
test can unmask signs like dyspnoea, angina pectoris, and inadequate rise in blood pressure, 
complex ventricular arrhythmias or repolarisation abnormalities, and dizziness. Patients 
suffering from symptoms during exercise have an event-free survival rate of lower than 20% 
within 2 years, whereas patients with a normal exercise tolerance have a survival rate of 
over 80% at 5 years (Iung, 2011). A positive exercise test is associated with a 7 times higher 
clinical event rate (Amato et al., 2001).  
The exercise test should be interrupted for limiting dyspnoea and fatigue, any angina or 
dizziness, > 2mm ST depression, any decrease in systolic blood pressure (> 20 mmHg or a 
fall compared to baseline), and complex ventricular ectopy. The exercise test should be 
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considered abnormal if exercise tolerance is < 80% according to age- and sex-adjusted levels. 
The type of exercise test-induced symptom is important for the outcome. Patients with 
dizziness on exertion have an 83% probability for proximate developing of symptoms, 
whereas with breathlessness or chest tightness it is only 54%, respectively 50% (Dal-Bianco 
et al., 2008). 
 
 
Fig. 5. Intraoperative view of a severely calcified  and stenotic aortic valve. 
2.7 Cardiac catherization 
The role of invasive assessment of aortic stenosis severity has decreased in the last decades, 
mainly due to the diagnostic power of echocardiography. Passage through a stenotic valve 
may lead to peripheral embolism. The main indication of cardiac catherization is nowadays 
to perform coronary angiography at symptom onset. Multislice computed tomography may 
be used in young patients with a low probabilty of coronary artery disease instead, but this 
method is limited in older patients because of coronary calcification causing blooming 
artefacts. Using specific catheters, simultaneous evaluation of the proximal aortic and left 
ventricular pressures yields the most accurate data. It is important to distinguish the 
maximum instantenous gradient from the mean and peak-to-peak gradients, when 
comparing to echocardiographic measurements. Right heart catherization is often 
performed to assess cardiac output by either the Fick principle or the indicator dilution 
technique, which allows aortic valve area calculation by the Gorlin formula. 
2.8 Chest X-ray 
Poststenotic dilatation of the aorta ascendens is often the main chest X-ray finding in 
patients with aortic stenosis, whereas cardiac silhouette shows no or only minor 
enlargement.  Calcification of the aortic valve is hardly seen on chest X-ray, in contrast to 
flouroscopy or electron-beam / multislice computed tomography (see below). 
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Fig. 6. Invasive assessment of aortic stenosis. Simultaneous measurement of left ventricular 
and aortic pressures (left side), showing a significant pressure gradient indicating severe 
aortic stenosis. This gradient disappears after pull-back of the tip of the catheter into the 
aorta ascendens (right side). 
2.9 Cardiac multislice computed tomography and cardiac magnetic resonance 
Although limited by the exposure to radiation, its availibity and its use in patients with high 
heart rate or atrial fibrillation, multislice computed tomography (MSCT) may be helpful in 
certain clinical situations in patients with aortic stenosis, e.g. diagnosis of coronary artery 
disease (Figure 3) or better assessment of aortic dilatation / aneurysm. Although lipid-
lowering therapy does not halt progression of moderate aortic stenosis, it is certainly indicated 
in the majority of patients because of concomitant coronary artery disease, as shown in the 
SEAS study and discussed below. MSCT is superior to quantify aortic valve calcification, 
although no cut-off point has been established yet influencing clinical decision making. It may 
also diagnose bicuspid valve morphology, and may even be helpful in assessment of valve 
area (Feuchtner et al., 2006). Cardiac MRI has been used in patients with asymptomatic aortic 
stenosis as well, but is not suitable for detection of concomitant coronary disease. Both MSCT 
and MRI have the limitation that they measure the anatomic and not the functional effective 
AVA, so the AS severity is often underrated. The velocity- encoded phase contrast imaging is a 
new magnetic resonance imaging technique, which allows aortic valve area quantification 
with the continuity equation imitating echocardiographic Doppler quantification. It is helpful 
in patients with poor echochardiographic windows, obesity, lung disease, or heavily calcified 
aortic valve (Dal-Bianco et al., 2008).  
3. Clinical issues in asymptomatic aortic stenosis 
3.1 Prognosis 
The natural history of asymptomatic patients with moderate to severe aortic stenosis is not 
benign. One half of patients with mild-to-moderate aortic stenosis develop severe outflow 
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Fig. 7. Cardiac MSCT showing severe aortic valve calcification. On the left panel, 
poststenotic dilatation of the ascending aorta can be seen, whereas concomitant coronary 
artery calcification can be detected on the right panel. LCA denotes left coronary artery; 
RCA denotes right coronary artery. 
obstruction within 6 years (Rosenhek et al., 2004). A large prospective study of asymptomatic 
patients with severe aortic stenosis showed that freedom from cardiovascular death or aortic 
valve replacement at 1, 2 and 5 years were only 80%, 63% and 20%, respectively. (Pellikka et 
al., 2005). This is particularly true for patients with very severe aortic stenosis, whose event-
free survival is only 64%, 36%, 25% and 12% at 1, 2, 3 and 4 years, respectively (Rosenhek et al., 
2009). Furthermore, patients with a peak systolic velocity > 5.5 m/s not referred to elective 
surgery present with severe symptom onset (defined by NYHA functional class > II), which is 
associated with a worse perioperative outcome.  
A survival analysis from 1968 from Ross and Braunwald showed that patients with aortic 
stenosis who had developed angina and syncope survived 3 years, patients with dyspnoea 2 
years, and patients with heart failure survived only 1 to 2 years. This study included 
symptomatic patients with heterogeneous AS etiology, thus not only calcific aortic stenosis. 
3.2 Noncardiac surgery risk 
Aortic stenosis is a risk factor for perioperative mortality and nonfatal myocardial infarction, 
but it is unclear whether aortic valve surgery should precede noncardiac surgery. 
Complication rates are  depending on the severity of aortic stenosis and the type of noncardiac 
surgery performed.  Perioperative complications may occurr in up to 11% of patients with 
moderate aortic stenosis and 31% of patients with severe aortic stenosis, as compared to 2% in 
matched patients without aortic stenosis (Kertai et al., 2004). In experienced centers, low or 
intermediate risk noncardiac surgery can be performed safely even in patients with severe 
asymptomatic aortic stenosis with a low myocardial infarction rate of around 3%, if there is 
prompt vasopressor therapy for hypotensive episodes (Calleja et al., 2010). 
3.3 Endocarditis prophylaxis 
In 2009, the ESC guidelines concerning antibiotic endocarditis prophylaxis have changed 
limiting its use to only high-rik patients, such as patients with prosthetic valves, previous 
infective endocarditis or certain congenital heart disease. Degenerative aortic stenosis is not 
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an indication for antibiotic endocarditis prophylaxis, even if a bicuspid aortic valve is 
present (Habib et al., 2009).  
3.4 Aggressive cardiovascular risk factor intervention 
As mentioned above, arterial hypertension puts additional load to the left ventricle in 
patients with aortic stenosis, and should be carefully treated. However, hypotensive 
episodes have to be avoided, and regular blood pressure measurements are mandatory. 
Retrospective studies suggested that lipid-lowering with statins might slow the progression 
of aortic stenosis, but prospective studies such as SALTIRE (Cowell et al., 2005) or SEAS 
(Rossebo et al., 2008) could not confirm such a positive effect on aortic valve events in 
patients with a LDL cholesterol below 140 mg/dl. Nevertheless, the majority of the patients 
with aortic stenosis need statins because of three reasons: 
 concomitant coronary artery disease: in SEAS, intensive lipid-lowering therapy with 
simvastin 40 mg and ezetimibe 10 mg/d daily reduced cardiovascular ischemic events 
even in patients with baseline LDL cholesterol below 140 mg/dl, mainly driven by a 
significant reduction in the need of additional bypass grafting when aortic valve 
replacement became mandatory; notably, LDL cholesterol were reduced by 61.3% to 
mean 55 mg/dl.  
 hypercholesterolemia: RAAVE, the only prospective study showing a slowing effect on 
the hemodynamic progression of aortic stenosis, was performed in 
hypercholesterolemic patients, defined by a LDL cholesterol above 160 mg/dl (Moura 
et al., 2007); therefore, such patients should receive statin therapy.   
 early stage of the disease: a retrospective analysis of 1046 patients (Antonini-Canterin, 
et al., 2008) could show that statin therapy slowed hemodynamic progression in the 
early stages of the disease process, e.g. aortic sclerosis or mild aortic stenosis. However, 
this effect disappeared in patients with more advanced aortic stenosis (defined by a 
baseline peak aortic velocity between 3 and 4 m/s). 
 
 
Fig. 8. Cardiac MSCT examinations showing the effects of newly initiated statin treatment 
on concomitant coronary artery disease. MPR denotes multiplanar reformation; VRT 
denotes volume-rendering technique; N denotes non-calcified atherosclerotic plaque; YOM 
denotes year old man. 
www.intechopen.com
 
Aortic Stenosis – Etiology, Pathophysiology and Treatment 
 
62
3.5 Recommended intervals for follow-up examinations 
For asymptomatic patients with aortic stenosis, close follow-up is imperative. Clinical 
evaluation should be performed once a year in patients with mild or moderate aortic 
stenosis and every 6 months in patients with severe aortic stenosis. Patients need to be 
questioned thoroughly about symptoms and exercise levels, along with the assessment and 
treatment of cardiovascular risk factors. Any change in symptoms should prompt the 
physician to perform a transthoracic echocardiography. Otherwise, intervals between 
echocardiography examinations are 3 - 5 years in patients with mild aortic stenosis, 1 - 2 
years in patients with moderate aortic stenosis and 6 months to 1 year in patient with severe 
stenosis. In patients with severe asymptomatic aortic stenosis, exercise testing and 
measurement of natriuretic peptide levels may be helpful. 
3.6 Bicuspid aortic valve disease  
Bicuspid aortic valve is the most common inherited valve abnormality, affecting 1 - 2% of all 
individuals. There is a genetic component which may justify familiy testing. Around 40% of 
patients with bicuspid Aortic valves often suffer from dilatation of the ascending aorta as well, 
independent of the severity of aortic stenosis and/or insufficiency. A major risk of aortic 
dilation in these patients is aortic dissection, being 9 times higher for patients with a bicuspid 
aortic valve than for patients with a tricuspid valve. If the maximum diameter is ≥ 5 cm with a 
fast progression rate above 0.5 cm2/year, surgery may be considered even in asymptomatic 
patients (Class IIaC indication according to ESC guidelines). Therefore, echocardiography 
should always include measurement of the diameter of the ascending aorta. If dilatation 
predominates above the sinotubular junction, diagnosis can be missed by transthoracic 
echocardiography and additional imaging techniques should be considered. Otherwise, 
management of bicuspid aortic valve disease is similar to that of tricuspid valve disease. 
 
 
Fig. 9. Using transesophageal echocardiography in a patient with calcific aortic stenosis, a 
biscupid valve morphology is detected and planimetry of the aortic valve area can be 
reliably performed. 
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Fig. 10. Complications associated with bicuspid aortic valve disease: endocarditis (left panel) 
and acute aortic dissection (right panel). 
3.7 Balancing risks between earlier surgery and watchful waiting 
Besides a positive exercise test, no single risk factor is an absolute criterion to predict poor 
clinical outcome in patients with asymptomatic severe aortic stenosis so far. Other indicators 
of high-risk such as rapid hemodynamic progression, heavy valve calcification or increased 
natriuretic peptide levels should be weightened against the risk of surgery.  
Fortunately, operative risk of isolated aortic valve replacement has dramatically declined 
over the last decades, currently being 2 - 5% in patients < 70 years and 5 – 15% in patients 
above 70 years. Concomitant bypass surgery increases the perioperative risk by around 5%. 
The EuroSCORE or the Society of Thoracic Surgeons predicted risk of mortality (STS-
PROM) score are commonly used for the evaluation of the preoperative risk for cardiac 
surgery. The simple additive EuroSCORE model is easy to use, even at the bedside. In high 
risk patients, however, the simple additive model often underestimates the risk when 
certain combinations of risk factors co-exist, and the logististic EuroSCORE should be used. 
It takes into consideration age, sex, chronic pulmonary disease, extracardiac arteriopathy, 
neurological dysfunction, previous cardiac surgery, renal insufficiency, active endocarditis, 
critical preoperative state, as well as cardiac-related factors such as unstable angina, left 
ventricular function, recent myocardial infarction and pulmonary hypertension. 
If a watchful waiting strategy is chosen, the patient should be educated and advised to self-
report onset of new symptoms to physician immediately. Patients often reduce 
subconsciously their physical activity, and so only a stress testing can uncover symptoms. 
3.8 The comorbid and elderly patient – considerations on transcatheter aortic valve 
implantation 
A third of patients with severe symptomatic aortic stenosis are not referred for valve 
replacement. This is mainly a problem for elderly patients, because many physcians ignore 
the fact that age itself is not a contra-indication to aortic valve implantation. The 
EuroSCORE or the STS-PROM score are commonly used to estimate the preoperative risk 
for cardiac surgery. Both scores incorporate various comorbidities such as chronic 
pulmonary disease and renal insufficiency; if a patient has too grave comorbidities he might 
be deemed inoperable. The approach to comorbid symptomatic patients is solid risk 
evaluation in experienced medical centers with a high surgery volume (“heart team”). 
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Interventional cardiologist more and more challenge heart surgeons by the introduction of 
transcatheter aortic valve implantation (TAVI), and the years to come will show if this new 
procedure may play a role also in younger patients with moderate preoperative risk.  
On the basis of current clinical outcome data, for symptomatic patients with severe aortic 
stenosis and a life expectancy over 1 year, indications for TAVI are definite 
contraindications to surgery or when surgery is estimated very high risk and if there are no 
barriers to TAVI. 
The results of TAVI are preliminary and any conclusions carry limitations. It seems that 
TAVI is practicable and present acceptable clinical and hemodynamic results up to 3 years. 
However, there are still major limitations for TAVI, e.g. paravalvular leaks causing 
significant aortic insufficiency, a higher postoperative need for pacemaker implantation or 
vascular complications. Bicuspid aortic valve morphology is not suitable for TAVI as well. 
The access for transcatheter aortic valve implantation is retrograde via the femoral or the 
subclavian artery or antegrade through a transapical approach.  
4. Conclusions 
Besides coronary artery disease and arterial hypertension, aortic stenosis is the third most 
common cardiovascular disorder in the Western World, affecting more than four percent of 
the population above 75 years. It is easy to diagnose by auscultation and subsequent 
transthoracic echocardiography. Surgical aortic valve implantation (SAVI) offers a very 
good therapeutic option for symptomatic patients with severe valve obstruction which has a 
dismal prognosis if left untreated. In contrast, the decision to operate on asymptomatic 
patients remains a controversity. Unfortunately, there is still no medical therapy available to 
prevent the development or to delay the progression of aortic stenosis. Probably, medical 
intervention would be most effective in early stages of the disease, even before obstruction 
of the left ventricular outflow occurs. This condition called aortic sclerosis is present in 25% 
of adults over 65 years of age. Currently, around 15% of these patients progress to 
hemodynamically significant aortic stenosis, and it would be of great importance to stop this 
active process more effectively in these patients.   
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